ID
45144
Descripción
Principal Investigator: Stephen Rich, PhD, University of Virginia, Charlottesville, VA, USA MeSH: Myocardial Infarction,Brain Ischemia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000402 The NHLBI "Grand Opportunity" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the "exome") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO. HeartGO is a consortium of six well-phenotyped NHLBI cohorts: Atherosclerosis Risk in Communities (ARIC) study, the Coronary Artery Risk Development in Young Adults (CARDIA) study, the Cardiovascular Health Study, the Framingham Heart Study, the Jackson Heart Study, and the Multi-Ethnic Study of Atherosclerosis. Together, these cohorts have provided DNA and phenotype datasets from a diverse cohort of individuals of African-American, Caucasian, Asian, and Hispanic ancestry to be made available for use by qualified investigators in dbGaP. HeartGO investigators will conduct genotype-phenotype analyses for phenotypes related not only to heart disease but with other variables that will be contributed to dbGaP. The HeartGO dataset provides investigators with genotype-phenotype analytic opportunities for traits not only related to heart disease but also associated with ancillary variables that will be contributed to dbGaP, including disease endpoints, risk factors, biomarkers, and subclinical disease measures. The phenotypes planned for investigation as part of the GO-ESP HeartGO project include early-onset myocardial infarction (EOMI), low density lipoprotein (LDL) cholesterol, body mass index/type 2 diabetes (BMI/T2D), blood pressure and ischemic stroke. Results of the proposed analyses as well as relevant replication/follow-up analyses will be reported in peer-reviewed journals. This study phs000402 contains the Jackson Heart Study (JHS) subset of GO-ESP/Heart-GO. Additional GO-ESP data is also available via dbGaP.
Link
Palabras clave
Versiones (2)
- 29/9/22 29/9/22 - Simon Heim
- 12/10/22 12/10/22 - Adrian Schulz
Titular de derechos de autor
Stephen Rich, PhD, University of Virginia, Charlottesville, VA, USA
Subido en
12 de octubre de 2022
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000402 NHLBI GO-ESP: Heart Cohorts Exome Sequencing Project (JHS)
Sample ID, subject ID, and using of samples obtained from participants involved in the " National Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts Component of the Exome Sequencing Project (JHS) " project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, subject source ID, and consent groups of participants involved in the " National Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts Component of the Exome Sequencing Project (JHS) " project.
- Sample ID, subject ID, and using of samples obtained from participants involved in the " National Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts Component of the Exome Sequencing Project (JHS) " project.
- Sociodemographic data including subject ID, sex, race, study site, study cohort, and age, family history of stroke, systolic and diastolic blood pressure, anthropometric data including BMI, body weight, body height, and waist in centimeters, laboratory measurement of blood including eosinophils, basophils, platelet count, red blood count, neutrophils, monocytes, lymphocytes, hematocrit, hemoglobin, Factor VIII, fasting glucose, fasting insulin, ICAM1 level, IL6 level, cystatin C, Digoxin, total cholesterol, triglycerides, HDL, LDL, C-reactive protein, Factor VII level, and Fibrinogen, uric acid, urinary albumin, and urinary creatinine, EKG including HR, PR, QRS, QT, and RR interval measurement, status of myocardial infraction, angioplasty, atrial fibrillation, atrioventricular block, hypertension, left ventricular hypertrophy, gout, and type 2 diabetes, coronary artery calcium Agatston and Framingham Risk Score, intimal-medial thickness, Wolf-Parkinson-White syndrome, treatment with medications, and smoking status of participants involved in the " National Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts Component of the Exome Sequencing Project (JHS) " project.
Similar models
Sample ID, subject ID, and using of samples obtained from participants involved in the " National Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts Component of the Exome Sequencing Project (JHS) " project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, subject source ID, and consent groups of participants involved in the " National Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts Component of the Exome Sequencing Project (JHS) " project.
- Sample ID, subject ID, and using of samples obtained from participants involved in the " National Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts Component of the Exome Sequencing Project (JHS) " project.
- Sociodemographic data including subject ID, sex, race, study site, study cohort, and age, family history of stroke, systolic and diastolic blood pressure, anthropometric data including BMI, body weight, body height, and waist in centimeters, laboratory measurement of blood including eosinophils, basophils, platelet count, red blood count, neutrophils, monocytes, lymphocytes, hematocrit, hemoglobin, Factor VIII, fasting glucose, fasting insulin, ICAM1 level, IL6 level, cystatin C, Digoxin, total cholesterol, triglycerides, HDL, LDL, C-reactive protein, Factor VII level, and Fibrinogen, uric acid, urinary albumin, and urinary creatinine, EKG including HR, PR, QRS, QT, and RR interval measurement, status of myocardial infraction, angioplasty, atrial fibrillation, atrioventricular block, hypertension, left ventricular hypertrophy, gout, and type 2 diabetes, coronary artery calcium Agatston and Framingham Risk Score, intimal-medial thickness, Wolf-Parkinson-White syndrome, treatment with medications, and smoking status of participants involved in the " National Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts Component of the Exome Sequencing Project (JHS) " project.
C1511726 (UMLS CUI [1,2])
C3846158 (UMLS CUI [1,3])
C0025663 (UMLS CUI [1,2])